Vlidaplit 50 Tablet contains Vildagliptin 50mg, an oral antidiabetic agent used in the management of Type 2 Diabetes Mellitus (T2DM). It is part of the DPP-4 (Dipeptidyl Peptidase-4) inhibitor class, which plays a vital role in regulating blood glucose levels by enhancing the body’s natural incretin hormones.
Incretins, such as GLP-1 and GIP, help regulate insulin secretion after meals and suppress glucagon release from the pancreas. Vildagliptin works by inhibiting the enzyme DPP-4, which normally breaks down these incretin hormones. By blocking DPP-4, Vlidaplit 50 increases incretin levels, thus promoting insulin secretion when blood sugar levels are high and reducing the amount of glucose produced by the liver.
Vlidaplit 50 is particularly effective in patients with mild to moderate hyperglycemia and is commonly prescribed either as monotherapy (especially in metformin-intolerant patients) or in combination with other antidiabetic agents such as metformin, sulfonylureas, or insulin. It provides significant improvement in HbA1c levels with a low risk of hypoglycemia, making it a suitable choice for long-term diabetes management.
Additionally, Vlidaplit 50 is generally well-tolerated, does not contribute to weight gain, and supports beta-cell preservation, which is crucial in slowing the progression of diabetes.
This tablet is most effective when used alongside lifestyle modifications such as a balanced diet, regular physical activity, and routine monitoring of blood glucose. It offers a modern and targeted approach to blood sugar regulation, improving both fasting and postprandial glucose levels.